Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | S100A9 | P06702 | 1/20 | 0.51 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252331 | 0.84 | S100A9 (0.50) | TAAR1S100A9PNMTCNR1CNR2 | |
| SCHEMBL18571236 | 0.84 | S100A9 (0.50) | TAAR1S100A9PNMTCNR1CNR2 | |
| SCHEMBL16914842 | 0.82 | CA1 (0.61) | TAAR1S100A9PNMTKMT2ARXFP1 | |
| SCHEMBL16000102 | 0.81 | CNR1 (0.53) | TAAR1S100A9PNMTCNR1CNR2 | |
| SCHEMBL10154047 | 0.80 | ACLY (0.49) | TAAR1KMT2APGRIDO1 | |
| SCHEMBL2377120 | 0.79 | PNMT (0.50) | TAAR1S100A9PNMTCHRM2CYP3A4 | |
| SCHEMBL14039772 | 0.79 | NOS1 (0.37) | S100A9 | |
| SCHEMBL26212941 | 0.79 | S100A9 (0.49) | TAAR1S100A9PNMTCNR1CNR2 | |
| SCHEMBL30270505 | 0.79 | S100A9 (0.49) | TAAR1S100A9PNMTCNR1CNR2 | |
| SCHEMBL3487099 | 0.79 | ALDH1A1 (0.54) | TAAR1S100A9KMT2ARXFP1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007108743-A2 | NOVEL QUINAZOLINES AS 5-HT6 MODULATORS II | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | claimed |
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-2772480-B1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9199959-B2 | HIV replication inhibitor | SHIONOGI & CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| WO-2007108743-A2 | NOVEL QUINAZOLINES AS 5-HT6 MODULATORS II | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | TAAR1 2247/4885S100A9 4533/4885PNMT 3813/4885 |
| US-20140249306-A1 | HIV REPLICATION INHIBITOR | SSU72, RTF2, ZC3HAV1 | TAAR1 3008/4885S100A9 4305/4885PNMT 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.